Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine

Sevasti Gaspari, Maria M. Papachatzaki, Ja Wook Koo, Fiona B. Carr, Maria Efstratia Tsimpanouli, Eugenia Stergiou, Rosemary C. Bagot, Deveroux Ferguson, Ezekiell Mouzon, Sumana Chakravarty, Karl Deisseroth, Mary Kay Lobo, Venetia Zachariou

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Regulator of G protein signalling 9-2 (Rgs9-2) modulates the actions of a wide range of CNS-acting drugs by controlling signal transduction of several GPCRs in the striatum. RGS9-2 acts via a complex mechanism that involves interactions with Gα subunits, the Gβ5 protein, and the adaptor protein R7BP. Our recent work identified Rgs9-2 complexes in the striatum associated with acute or chronic exposures to mu opioid receptor (MOR) agonists. In this study we use several new genetic tools that allow manipulations of Rgs9-2 activity in particular brain regions of adult mice in order to better understand the mechanism via which this protein modulates opiate addiction and analgesia. We used adeno-associated viruses (AAVs) to express forms of Rgs9-2 in the dorsal and ventral striatum (nucleus accumbens, NAc) in order to examine the influence of this protein in morphine actions. Consistent with earlier behavioural findings from constitutive Rgs9 knockout mice, we show that Rgs9-2 actions in the NAc modulate morphine reward and dependence. Notably, Rgs9-2 in the NAc affects the analgesic actions of morphine as well as the development of analgesic tolerance. Using optogenetics we demonstrate that activation of Channelrhodopsin2 in Rgs9-2-expressing neurons, or in D1 dopamine receptor (Drd1)-enriched medium spiny neurons, accelerates the development of morphine tolerance, whereas activation of D2 dopamine receptor (Drd2)-enriched neurons does not significantly affect the development of tolerance. Together, these data provide new information on the signal transduction mechanisms underlying opiate actions in the NAc.

Original languageEnglish (US)
Pages (from-to)1968-1977
Number of pages10
JournalNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Volume39
Issue number8
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

GTP-Binding Protein Regulators
Nucleus Accumbens
Morphine
Neurons
Adaptor Protein Complex Subunits
Analgesics
Opiate Alkaloids
Signal Transduction
Optogenetics
Morphine Dependence
Opioid-Related Disorders
Dopamine D1 Receptors
Dependovirus
Proteins
Dopamine D2 Receptors
mu Opioid Receptor
Reward
Knockout Mice
Analgesia
Brain

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine. / Gaspari, Sevasti; Papachatzaki, Maria M.; Koo, Ja Wook; Carr, Fiona B.; Tsimpanouli, Maria Efstratia; Stergiou, Eugenia; Bagot, Rosemary C.; Ferguson, Deveroux; Mouzon, Ezekiell; Chakravarty, Sumana; Deisseroth, Karl; Lobo, Mary Kay; Zachariou, Venetia.

In: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Vol. 39, No. 8, 2014, p. 1968-1977.

Research output: Contribution to journalArticle

Gaspari, S, Papachatzaki, MM, Koo, JW, Carr, FB, Tsimpanouli, ME, Stergiou, E, Bagot, RC, Ferguson, D, Mouzon, E, Chakravarty, S, Deisseroth, K, Lobo, MK & Zachariou, V 2014, 'Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine', Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, vol. 39, no. 8, pp. 1968-1977. https://doi.org/10.1038/npp.2014.45
Gaspari, Sevasti ; Papachatzaki, Maria M. ; Koo, Ja Wook ; Carr, Fiona B. ; Tsimpanouli, Maria Efstratia ; Stergiou, Eugenia ; Bagot, Rosemary C. ; Ferguson, Deveroux ; Mouzon, Ezekiell ; Chakravarty, Sumana ; Deisseroth, Karl ; Lobo, Mary Kay ; Zachariou, Venetia. / Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine. In: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2014 ; Vol. 39, No. 8. pp. 1968-1977.
@article{05dc91ac7ed5497eb532ece3f4d21ec9,
title = "Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine",
abstract = "Regulator of G protein signalling 9-2 (Rgs9-2) modulates the actions of a wide range of CNS-acting drugs by controlling signal transduction of several GPCRs in the striatum. RGS9-2 acts via a complex mechanism that involves interactions with Gα subunits, the Gβ5 protein, and the adaptor protein R7BP. Our recent work identified Rgs9-2 complexes in the striatum associated with acute or chronic exposures to mu opioid receptor (MOR) agonists. In this study we use several new genetic tools that allow manipulations of Rgs9-2 activity in particular brain regions of adult mice in order to better understand the mechanism via which this protein modulates opiate addiction and analgesia. We used adeno-associated viruses (AAVs) to express forms of Rgs9-2 in the dorsal and ventral striatum (nucleus accumbens, NAc) in order to examine the influence of this protein in morphine actions. Consistent with earlier behavioural findings from constitutive Rgs9 knockout mice, we show that Rgs9-2 actions in the NAc modulate morphine reward and dependence. Notably, Rgs9-2 in the NAc affects the analgesic actions of morphine as well as the development of analgesic tolerance. Using optogenetics we demonstrate that activation of Channelrhodopsin2 in Rgs9-2-expressing neurons, or in D1 dopamine receptor (Drd1)-enriched medium spiny neurons, accelerates the development of morphine tolerance, whereas activation of D2 dopamine receptor (Drd2)-enriched neurons does not significantly affect the development of tolerance. Together, these data provide new information on the signal transduction mechanisms underlying opiate actions in the NAc.",
author = "Sevasti Gaspari and Papachatzaki, {Maria M.} and Koo, {Ja Wook} and Carr, {Fiona B.} and Tsimpanouli, {Maria Efstratia} and Eugenia Stergiou and Bagot, {Rosemary C.} and Deveroux Ferguson and Ezekiell Mouzon and Sumana Chakravarty and Karl Deisseroth and Lobo, {Mary Kay} and Venetia Zachariou",
year = "2014",
doi = "10.1038/npp.2014.45",
language = "English (US)",
volume = "39",
pages = "1968--1977",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine

AU - Gaspari, Sevasti

AU - Papachatzaki, Maria M.

AU - Koo, Ja Wook

AU - Carr, Fiona B.

AU - Tsimpanouli, Maria Efstratia

AU - Stergiou, Eugenia

AU - Bagot, Rosemary C.

AU - Ferguson, Deveroux

AU - Mouzon, Ezekiell

AU - Chakravarty, Sumana

AU - Deisseroth, Karl

AU - Lobo, Mary Kay

AU - Zachariou, Venetia

PY - 2014

Y1 - 2014

N2 - Regulator of G protein signalling 9-2 (Rgs9-2) modulates the actions of a wide range of CNS-acting drugs by controlling signal transduction of several GPCRs in the striatum. RGS9-2 acts via a complex mechanism that involves interactions with Gα subunits, the Gβ5 protein, and the adaptor protein R7BP. Our recent work identified Rgs9-2 complexes in the striatum associated with acute or chronic exposures to mu opioid receptor (MOR) agonists. In this study we use several new genetic tools that allow manipulations of Rgs9-2 activity in particular brain regions of adult mice in order to better understand the mechanism via which this protein modulates opiate addiction and analgesia. We used adeno-associated viruses (AAVs) to express forms of Rgs9-2 in the dorsal and ventral striatum (nucleus accumbens, NAc) in order to examine the influence of this protein in morphine actions. Consistent with earlier behavioural findings from constitutive Rgs9 knockout mice, we show that Rgs9-2 actions in the NAc modulate morphine reward and dependence. Notably, Rgs9-2 in the NAc affects the analgesic actions of morphine as well as the development of analgesic tolerance. Using optogenetics we demonstrate that activation of Channelrhodopsin2 in Rgs9-2-expressing neurons, or in D1 dopamine receptor (Drd1)-enriched medium spiny neurons, accelerates the development of morphine tolerance, whereas activation of D2 dopamine receptor (Drd2)-enriched neurons does not significantly affect the development of tolerance. Together, these data provide new information on the signal transduction mechanisms underlying opiate actions in the NAc.

AB - Regulator of G protein signalling 9-2 (Rgs9-2) modulates the actions of a wide range of CNS-acting drugs by controlling signal transduction of several GPCRs in the striatum. RGS9-2 acts via a complex mechanism that involves interactions with Gα subunits, the Gβ5 protein, and the adaptor protein R7BP. Our recent work identified Rgs9-2 complexes in the striatum associated with acute or chronic exposures to mu opioid receptor (MOR) agonists. In this study we use several new genetic tools that allow manipulations of Rgs9-2 activity in particular brain regions of adult mice in order to better understand the mechanism via which this protein modulates opiate addiction and analgesia. We used adeno-associated viruses (AAVs) to express forms of Rgs9-2 in the dorsal and ventral striatum (nucleus accumbens, NAc) in order to examine the influence of this protein in morphine actions. Consistent with earlier behavioural findings from constitutive Rgs9 knockout mice, we show that Rgs9-2 actions in the NAc modulate morphine reward and dependence. Notably, Rgs9-2 in the NAc affects the analgesic actions of morphine as well as the development of analgesic tolerance. Using optogenetics we demonstrate that activation of Channelrhodopsin2 in Rgs9-2-expressing neurons, or in D1 dopamine receptor (Drd1)-enriched medium spiny neurons, accelerates the development of morphine tolerance, whereas activation of D2 dopamine receptor (Drd2)-enriched neurons does not significantly affect the development of tolerance. Together, these data provide new information on the signal transduction mechanisms underlying opiate actions in the NAc.

UR - http://www.scopus.com/inward/record.url?scp=84902547298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902547298&partnerID=8YFLogxK

U2 - 10.1038/npp.2014.45

DO - 10.1038/npp.2014.45

M3 - Article

C2 - 24561386

AN - SCOPUS:84902547298

VL - 39

SP - 1968

EP - 1977

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 8

ER -